Registry for patients with neurocutaneous melanocytosis and large cutaneous nevi
Official title: Prospective Registry of Patients With Neurocutaneous Melanocytosis (NCM) Including Cutaneous and CNS Involvement
Run by Memorial Sloan Kettering Cancer Center · NCT04548817 · Data updated 2026-11-12
This study is collecting information from people of all ages who have large skin moles or neurocutaneous melanocytosis to understand their medical care and any related health issues.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 2 sites (Boston, Massachusetts and 1 other locations) |
| Status | Recruiting |
| Started | September 3, 2020 |
| Main results expected | September 3, 2027 |
| Study ends | September 3, 2027 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT04548817 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals of any age with diagnosed LCMN or NCM, including those with associated CNS melanocytosis.
✕Probably not a fit
Patients without LCMN or NCM, or those who do not meet the inclusion criteria, may not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry collects information on patients diagnosed with large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM). It aims to gather data regarding the regular medical care these patients receive, including their clinical presentations and any associated conditions. The study includes patients of all ages and allows for the inclusion of deceased patients under specific conditions. The registry does not require mandatory pathology reviews for diagnosis confirmation if characteristic skin lesions are present.
Why it matters
Potential benefit: If successful, this registry could enhance understanding and management of neurocutaneous melanocytosis and related conditions, leading to improved patient care.
How similar studies have gone: While this registry approach is not widely tested, similar observational studies have successfully contributed to understanding rare conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with LCMN, defined as: * Dark-colored patch of skin present at birth * Can be located anywhere on the individual's skin * May include satellite lesions * May be associated with hypertrichosis OR, in absence of cutaneous involvement: * histologically or radiographically confirmed CNS melanocytosis. * Any age at diagnosis. * Signed informed consent by a patient, or parent/legal guardian. * Deceased patients can be included provided that parent/legal guardian is contacted at least 6 months after the death of the child and not on the child's birthday or anniversary of death. Pathology review at MSK is not mandatory to confirm the diagnosis of LCMN or NCM. We will not require pathology analysis of leptomeningeal deposits in patients where characteristic skin lesions are present and melanosis of the meninges is radiographically evident. However, if pathology samples have already been obtained as part of a patient's evaluation and treatment at another institution, tissue samples will be requested for review and confirmation of the diagnosis. Exclusion Criteria: * Informed consent has not been provided.
Where it's running
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States Recruiting -
Boston Children's Hospital (Data Analysis Only)
Boston, Massachusetts, United States Not yet recruiting
Study contacts
- Principal investigator: Yasmin Khakoo, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Yasmin Khakoo, MD
- Email: khakooy@mskcc.org
- Phone: 212-639-8292
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Guiding melanoma surgery in children using pathology and genetics
This pediatric phase 2 trial tests whether using tumor pathology and genetic information to classify risk can guide safer, more appropriate surgery for localized skin melanocytic tumors.
-
Gathering health information for younger cancer patients
This study is gathering health information from younger cancer patients to help improve treatments and support future research.
-
AI tool helps dermatologists decide if a skin lesion could be melanoma
A computer tool called DEXI tested with DermaGraphix Visualizer helps dermatologists see if a skin lesion might be melanoma and aims to reduce unnecessary biopsies.
-
Confocal imaging and genetic testing of atypical moles and early melanoma
This project will try to see if noninvasive confocal images of suspicious moles match genetic changes from sequencing in adults who are having the lesions removed.
-
Understanding the genetic causes of moles
This study is trying to find out the genetic changes that cause moles by looking at DNA from skin samples and blood to better understand these common skin growths.
-
Understanding how normal skin cells change to melanoma
This study is trying to understand how normal skin cells change into melanoma in children and young adults with certain types of moles to help improve early diagnosis and treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.